---
title: "Satellos Bioscience gibt Ausgabe von Optionsscheinen und Aktien bekannt"
description: "Satellos Bioscience Inc. announced the issuance of pre-funded warrants for a total of 495,049 common shares as part of a public offering in Canada and the U.S. The warrants were offered at a price of "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275367979.md"
published_at: "2026-02-09T22:00:18.000Z"
---

# Satellos Bioscience gibt Ausgabe von Optionsscheinen und Aktien bekannt

> Satellos Bioscience Inc. announced the issuance of pre-funded warrants for a total of 495,049 common shares as part of a public offering in Canada and the U.S. The warrants were offered at a price of $10.09999 each, reflecting the share issuance price minus an exercise price of $0.00001 CAD per share.

Satellos Bioscience Inc. hat bekanntgegeben, dass im Rahmen eines öffentlichen Angebots in Kanada und den USA Optionsscheine (pre-funded warrants) auf den Erwerb von insgesamt 495.049 Stammaktien ausgegeben wurden. Diese wurden zu einem Preis von 10,09999 US-Dollar pro Optionsschein angeboten, entsprechend dem Ausgabepreis der Stammaktien abzüglich des Ausübungspreises von 0,00001 kanadischen Dollar pro Aktie. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209211048) on February 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [MSLE.US - Satellos Bioscience](https://longbridge.com/en/quote/MSLE.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [LABD.US - Direxion S&P Biotech Bear 3X](https://longbridge.com/en/quote/LABD.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| AI 制药企业 Generate BiomedicinesIPO 定价 16 美元/股 今晚登陆纳斯达克 | AI 药物研发公司 Generate Biomedicines 正式公布 IPO 发行价为每股 16 美元，计划今晚在纳斯达克上市，发行 2500 万股，募资 4 亿美元。该公司专注于免疫学与肿瘤学，利用人工智能技术开发药物，三款蛋白质药物 | [Link](https://longbridge.com/en/news/277153682.md) |
| 新冠疫苗制造商诺瓦瓦克斯因销售额攀升而扭亏为盈 | 诺瓦瓦克斯公司（纳斯达克股票代码：NVAX）因销售额攀升而扭亏为盈，第四季度每股收益为 11 美分，营收为 1.47 亿美元，同比增长 67%。公司超额完成 2025 年成本削减目标，并预计 2026 年研发与销售及管理费用为 3.25 亿 | [Link](https://longbridge.com/en/news/277089687.md) |
| 围攻侏儒症 “药王” | 侏儒症的治疗正迎来变革。BioMarin 的 Vosoritide 是首个获批药物，预计 2025 年销售额达 9.27 亿美元，但多款新药正在挑战其市场地位。Ascendis 的 TransCon-CNP 和 BridgeBio 的 In | [Link](https://longbridge.com/en/news/277272274.md) |
| 中邮证券：siRNA 药物机制优势突出 递送为核心技术 | 中邮证券发布研报指出，siRNA 药物在精准沉默致病蛋白方面具有显著优势，递送系统是核心技术。与传统小分子和生物药相比，siRNA 药物的核酸疗法已成为新药开发的热门方向。海外企业如 Alnylam、Arrowhead 等已进入临床后期，国 | [Link](https://longbridge.com/en/news/277137610.md) |
| Artisan Partners Limited Partnership 增加了其在 Twist Bioscience Corporation $TWST 的股份 | Artisan Partners Limited Partnership 在第三季度将其在 Twist Bioscience Corporation (NASDAQ:TWST) 的持股增加了 26.7%，目前持有 6,410,900 股，价 | [Link](https://longbridge.com/en/news/277163890.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.